在造血干细胞移植前预处理方案中加入罗米司亭可在维持植入水平的同时减少化疗剂量
该研究在小鼠造血干细胞移植模型中测试,在临床使用的环磷酰胺联合白消安预处理方案中加入血小板生成素受体激动剂罗米司亭,是否能减少预处理化疗剂量而不降低后续移植造血干细胞的植入。结果显示罗米司亭不仅使造血干细胞对化疗更敏感,还使主要化疗成分白消安减半成为可能,同时在长期连续移植实验中维持造血干细胞植入水平。
要点
- 在小鼠造血干细胞移植模型中,预处理方案加入罗米司亭可提高环磷酰胺联合白消安方案的疗效。
- 罗米司亭使造血干细胞对化疗敏感,并允许白消安剂量减半。
- 在长期连续移植实验中,白消安减半后造血干细胞植入水平仍得以维持。
核心结论
- 在小鼠造血干细胞移植模型中,预处理期间加入罗米司亭可使主要化疗成分白消安剂量减半,同时在长期连续移植实验中维持造血干细胞植入水平。
研究设计与样本
- 研究采用小鼠造血干细胞移植模型,测试在临床应用的环磷酰胺联合白消安预处理方案中加入罗米司亭是否可减少预处理药物剂量而不降低后续移植造血干细胞植入。
主要发现
- 罗米司亭不仅使造血干细胞对化疗敏感,还使主要化疗成分白消安减半成为可能,同时在长期连续移植实验中维持造血干细胞植入水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative treatment approach for certain benign and malignant hematologic diseases. The actual HSCT is preceded by a conditioning therapy that reduces host-vs-HSCT graft rejection and creates niche space for transplanted hematopoietic stem and progenitor cells (HSPCs). Conditioning consists of chemotherapy with or without irradiation and is a major cause of side effects in HSCT. However, reduction of the intensity of cytotoxic conditioning leads to higher rates of engraftment failure and increased rates of relapse. We here tested if the addition of an HSC cycling inducing agent during conditioning allows to diminish the dose of conditioning drugs without reducing subsequent transplanted HSC engraftment in a mouse HSCT model. The thrombopoietin receptor agonist romiplostim was shown to induce cell cycling activity in hematopoietic stem cells (HSCs). We thus tested if the addition of romiplostim to the clinically applied conditioning chemotherapy regimen cyclophosphamide and busulfan leads to increased efficacy of the chemotherapeutic regimen. We found that romiplostim not only sensitizes HSCs to chemotherapy but also enables a reduction of the main chemotherapeutic component busulfan by half while HSC engraftment levels are maintained in long-term, serial transplantation assays.
引用
- Wilk CM, Kovtonyuk LV, Manz MG, et al. Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels. Blood Adv. 2022. PMID: 35736667. doi:10.1182/bloodadvances.2022007566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。